Embecta (EMBC) to Release Earnings on Tuesday

Embecta (NASDAQ:EMBC) will likely be issuing its Q4 2025 results before the market opens on Tuesday, November 25th. Analysts expect the company to announce earnings of $0.4550 per share and revenue of $265.6610 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 25, 2025 at 8:00 AM ET.

Embecta Stock Performance

EMBC opened at $14.31 on Tuesday. The stock has a market capitalization of $836.99 million, a PE ratio of 10.01, a price-to-earnings-growth ratio of 0.81 and a beta of 1.10. The stock’s 50 day moving average price is $14.17 and its 200-day moving average price is $12.42. Embecta has a 52-week low of $9.20 and a 52-week high of $21.48.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Zacks Research lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. BTIG Research reissued a “buy” rating and set a $25.00 price objective on shares of Embecta in a research note on Friday, September 5th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.00.

Institutional Trading of Embecta

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Larson Financial Group LLC increased its position in shares of Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after acquiring an additional 1,574 shares in the last quarter. Wexford Capital LP purchased a new stake in Embecta during the 3rd quarter valued at $94,000. Tower Research Capital LLC TRC increased its holdings in shares of Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after purchasing an additional 6,224 shares in the last quarter. iSAM Funds UK Ltd purchased a new position in shares of Embecta in the third quarter worth $115,000. Finally, FourThought Financial Partners LLC purchased a new position in shares of Embecta in the third quarter worth $155,000. 93.83% of the stock is currently owned by institutional investors.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.